-
Mashup Score: 2Email Restriction - 3 year(s) ago
Meeting Login Please enter the email you registered with and the password received via email. By logging in, you certify you are a Healthcare Professional. If you are not yet registered please click here to register for free. For any questions or assistance please contact iach@cme-congresses.com.
Source: iachlive.cme-congresses.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Combining CAR T-cell therapy with targeted drugs—can we improve efficacy in patients with R/R CLL? - 3 year(s) ago
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to William Wierda, MD Anderson Cancer Center, Houston, US. We asked, Can we improve efficacy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) by combining chimeric antigen receptor (CAR) T-cell therapy with targeted drugs?
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#IACH2021 | We talked about these novel combinations of CAR-Ts with targeted agents with @wwierda; listen to his insights below! https://t.co/AftBbPKWBK #CLL #leusm #leukemia
-
-
Mashup Score: 4VJHemOnc – The video journal of hematological oncology - 3 year(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
💥 It’s the final day of #IACH2021, but we still have so many incredible speakers lined up for today! 💥 We’ve got you covered for all updates – just visit https://t.co/O9p0vDBrzw for interviews with the speakers 👩⚕️👨⚕️ @VJHemOnc @TheIACH @Mohty_EBMT #MMsm #LEUsm #LYMsm #HemOnc https://t.co/1OXExpSrKZ
-
-
Mashup Score: 0Current challenges faced with CAR T-cell therapies - 3 year(s) ago
Christian Chabannon, MD, PhD, Institut Paoli Calmettes, Marseille, France, talks on the financial and sociological challenges associated with the use…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Christian Chabannon (@CChabannon) of @paoli_calmettes gives an overview of current challenges faced with CAR T-cell therapies 👨⚕️💭 Click to watch 👉https://t.co/NBxoOCvcwj👈 @VJHemOnc @TheIACH #IACH2021 #MMsm #LEUsm #LYMsm #HemOnc #tcellrx #CART
-
-
Mashup Score: 0Email Restriction - 3 year(s) ago
Meeting Login Please enter the email you registered with and the password received via email. By logging in, you certify you are a Healthcare Professional. If you are not yet registered please click here to register for free. For any questions or assistance please contact iach@cme-congresses.com.
Source: iachlive.cme-congresses.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Ongoing Live Stream – 4th Annual IACH Meeting @TheIACH #iach2021 https://t.co/fTPJVl7J0Z
-
-
Mashup Score: 0Registration - 3 year(s) ago
Registration Form Registration includes: – Access to the live program and on-demand program following the meeting – Access to the E-Poster Area – Access to the Industry Symposia – Access to the Exhibition Area – Opportunity to claim your CME accreditation points via the EBAH for attending this event Should you wish to obtain a personalized Certificate of Attendance,
Source: 4th Annual IACH MeetingCategories: Hem/Oncs, Latest HeadlinesTweet-
Registration – 4th Annual IACH Meeting @TheIACH #iach2021 https://t.co/3nRpsv2GiB
-
-
Mashup Score: 2Extended follow-up from the DREAMM-2 trial - 3 year(s) ago
The potential of belantamab mafodotin (belamaf) in the relapsed or refractory (R/R) multiple myeloma (MM) setting was highlighted in 2019, when the pivotal DREAMM-2 study met its primary endpoint.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#IACH2021 | The first one to be approved for relapsed/refractory #myeloma is belantamab mafodotin (belamaf) #mmsm Read the latest here👇 https://t.co/fSRmntQOpC
-
-
Mashup Score: 2FDA approval of zanubrutinib for adult patients with Waldenström’s macroglobulinemia - 3 year(s) ago
On September 1, 2021, it was announced that the U.S. Food and Drug Administration (FDA) approved the use of zanubrutinib, a small molecule Bruton’s tyrosine kinase inhibitor, for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In case you missed it 📢 On Sep 1st, the @US_FDA approved zanubrutinib for Waldenström’s macroglobulinemia based on the results of the ASPEN trial which favored zanubrutinib versus ibrutinib. #lymsm #IACH2021 Read more below: https://t.co/pJJWXbGA6U
-
-
Mashup Score: 4Transplant indications in AML - 3 year(s) ago
Arnon Nagler, MD, MSc, Chaim Sheba Medical Center, Tel-Hashomer, Israel, outlines the indications for transplantation in acute myeloid leukemia (AML)….
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Arnon Nagler (@nagler_EBMT) of the Chaim Sheba Medical Center gives an overview of transplant indications in AML at #IACH2021 👨⚕️💉 Watch here 👉https://t.co/yYLJ73OQrH👈 @VJHemOnc @TheIACH #MMsm #LEUsm #LYMsm #HemOnc #BMTsm
-
-
Mashup Score: 0IKEMA: Isatuximab in combination with the standard-of-care regimen carfilzomib + dexamethasone for the treatment of R/R multiple myeloma - 3 year(s) ago
In March 2021, the U.S. Food and Drug Administration (FDA) approved isatuximab in combination with carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma (MM) in patients who had received one to three prior lines of therapy.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#IACH2021 | @TomBmt133 focus on the carfilzomib-based combinations, highlighting the results of isatuximab + Kd in the IKEMA trial, a combination approved this year for RRMM ➡️ Read more here: https://t.co/Og089oitJD
-
RT @Mohty_EBMT: Ongoing Live Stream – 4th Annual IACH Meeting @TheIACH #iach2021 https://t.co/fTPJVl7J0Z